At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
Docetaxel +2 moredrug
Likely dose
Docetaxel 20mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Trial of Post-Prostatectomy Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic T2-T3NO (Tumor-3, Node-0) Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating Docetaxel, Radiation Therapy, and 1 other intervention for Prostate Cancer. Completed, enrolled 27 participants across 1 site.
Detailed Summary
Following a radical prostatectomy and lymph node sampling, eligible patients will undergo post-operative radiation therapy, concurrent weekly docetaxel chemotherapy , and hormonal therapy (Casodex daily and Zoladex every 3 months for 2 times or Lupron 22.5 mg im every 3 months for 2 times).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2008
Enrollment StartAug 2012
Primary CompletionAug 2016
Study CompletionApr 2017
TodayJul 2026
First PostedApr 29, 2008
Enrollment StartAug 1, 2012
Primary CompletionAug 1, 2016
Study CompletionApr 1, 2017
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 18.2 years ago
Interventions
Docetaxeldrug
20mg/m2 IV weekly for 7 weeks
Radiation Therapyradiation
66.0 Gy delivered in 33 daily fractions at 2.0 Gy/fx
Casodex and Zoladex (or Lupron)drug
Casodex 50 mg po daily for 6 months, and Zoladex 10.8 mg sc q 3 mos x 2 (or Lupron 22.5 mg im q 3 mos x 2)